MX2018015022A - Métodos para el tratamiento de la enfermedad de alzheimer. - Google Patents

Métodos para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2018015022A
MX2018015022A MX2018015022A MX2018015022A MX2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A MX 2018015022 A MX2018015022 A MX 2018015022A
Authority
MX
Mexico
Prior art keywords
disease
methods
treating alzheimer
subject
amyloid
Prior art date
Application number
MX2018015022A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Sevigny Jeffrey
Lugene Williams Leslie
Phillip Boot Brendon
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MX2018015022A publication Critical patent/MX2018015022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2018015022A 2016-06-07 2017-06-06 Métodos para el tratamiento de la enfermedad de alzheimer. MX2018015022A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US201662435531P 2016-12-16 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2018015022A true MX2018015022A (es) 2019-08-14

Family

ID=59067640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015022A MX2018015022A (es) 2016-06-07 2017-06-06 Métodos para el tratamiento de la enfermedad de alzheimer.

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN114796481A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
JOP20210265A1 (ar) 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
KR20220084095A (ko) * 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
US20240270830A1 (en) * 2021-06-07 2024-08-15 Biogen Ma Inc. Methods for treating alzheimer's disease
WO2023055733A1 (en) * 2021-09-30 2023-04-06 The Scripps Research Institute Compounds for reducing neuroinflammation
CA3237165A1 (en) * 2021-11-19 2023-05-25 Jeng-Horng Her Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153248A (en) * 2006-07-14 2015-01-29 Ac Immune Sa Humanized antibody against amyloid beta
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
SMT202000340T1 (it) * 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
US20150315267A1 (en) * 2012-12-07 2015-11-05 Thierry Bussiere A method of reducing brain amyloid plaques using anti-ab antibodies
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
CA2938466C (en) * 2014-02-08 2021-11-02 Genentech, Inc. Methods of treating alzheimer's disease
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
BR112018075300A2 (pt) 2019-04-30
IL263433A (en) 2019-01-31
US20200308259A1 (en) 2020-10-01
IL263433B1 (en) 2023-11-01
MA45149A (fr) 2019-04-10
US20220281963A1 (en) 2022-09-08
CN109476730A (zh) 2019-03-15
EP3464350A1 (en) 2019-04-10
AU2024216442A1 (en) 2024-10-17
KR20230165883A (ko) 2023-12-05
JP2025160337A (ja) 2025-10-22
JP2022145965A (ja) 2022-10-04
CA3026598A1 (en) 2017-12-14
KR20190021311A (ko) 2019-03-05
IL263433B2 (en) 2024-03-01
JP2019517540A (ja) 2019-06-24
AU2017276656A1 (en) 2018-12-13
WO2017211827A1 (en) 2017-12-14
CN114796481A (zh) 2022-07-29
CN114931635A (zh) 2022-08-23

Similar Documents

Publication Publication Date Title
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
MX2017014806A (es) Conjugados oligonucleotido- peptido.
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX388325B (es) Metodos de diagnostico para tratamiento con linfocitos t.
MX2017016806A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
CL2021001389A1 (es) Formulaciones en cápsula
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2017003513A (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato